Loading
A phase 2 trial of Tusamitamab ravtansine, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in Non-small-cell lung cancer, run by Sanofi, recorded as terminated on the registry.
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC is a phase 2 interventional study registered as NCT04524689 by Sanofi, with 57 participants recorded, started 2020-10-26 and due to reach its primary completion in 2024-03-12. Interventions recorded: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed. Conditions recorded: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC).
Linked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
57 enrolled.
95% CI 26.82 to 69.41; Figures from the ClinicalTrials.gov results section (first posted 2025-03-17), not from a publication · 95% CI 0.00 to 84.19
Source95% CI 36.35 to 79.29; Figures from the ClinicalTrials.gov results section (first posted 2025-03-17), not from a publication · 95% CI 9.43 to 99.16
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Doublet Cohort: Objective Response Rate (ORR)primary | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab | 23 | 47.8% | - | - | link |
| Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab | 2 | 0% | ||||
| Quadruplet Cohort: Objective Response Rateprimary | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed | 22 | 59.1% | - | - | link |
| Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed | 3 | 66.7% |
Shares Tusamitamab ravtansine, Sanofi, Non-small-cell lung cancer and the tag pipeline.
Shares Tusamitamab ravtansine, Sanofi and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.